We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The four impacted products, which are intended to be sterile, are sold under the brand names Equate, CVS Health and AACE Pharmaceuticals, and have expiration dates ranging from February 2024 to ...

Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...

Despite CVS Health's issues, its prospects and solid dividend program make it attractive for income seekers. Johnson & ...

Wells Fargo analyst Stephen Baxter maintained a Buy rating on CVS Health (CVS – Research Report) on January 10 and set a price target of ...